Drug transporter related research has grown exponentially in the last few years driven particularly by the emergence of the Food and Drug Administration (FDA) critical path transporter white paper and subsequent draft guidance from the FDA, European Medicines Agency, and Prescription Drug Marketing Act. Although considerable progress has been made over the past 15 years, the field of drug transport continues to evolve, particularly with respect to clinical translation of in vitro/preclinical data (Nat Rev Drug Discovery, 2010), understanding of systemic/tissue drug exposure implications, toxicity/disease pathogenesis, and the interplay between transporters and metabolism.
Goals and Objectives
The 2013 AAPS Workshop on Drug Transporters will deliver cutting edge science in a focused and ‘state of the art’ meeting. Key areas of focus will include:
a) the impact of drug molecules on physiological processes mediated by transporters;
b) regulation of transporter expression and function in health and disease;
c) state-of-the art sessions on:
(i) effective transporter assays and
(ii) emerging transporters and transporter sciences;
d) the importance of understanding intracellular concentrations of drug and metabolites;
e) transporters in translational medicine; and
f) an FDA-led session on regulatory perspectives on transporter-mediated drug-drug development evaluation during drug development, followed by an industry case study discussion forum.
This workshop is cosponsored by EUFEPS.